1 Apr, 2019

Aaron Tachibana

Aaron Tachibana joined Personalis as Chief Financial Officer in March 2019, with more than fifteen years of executive financial management experience at large, medium, and small cap public and private companies. Prior to Personalis, Mr. Tachibana was Chief Financial Officer at Lumentum from August 2015 to September 2018.  Lumentum is a publicly listed optical and [...]

3 Jan, 2019

Clinton Musil, MBA

Clinton Musil joined Personalis in January 2019 as Chief Business Officer.  Mr. Musil previously worked at ARMO Biosciences, where he oversaw the Company’s $147 million initial public offering and $1.6 billion sale to Eli Lilly. Clinton has expertise in corporate finance and mergers and acquisitions (M&A) from the healthcare industry, including raising several billion dollars [...]

5 Sep, 2017

Xavier Paliard Pharm.D., Ph.D.

Xavier Paliard joined Personalis in July 2017 as Vice President Immunology, Research & Development where he leads the strategy as well as R&D in the area of personalized cancer vaccines and other personalized therapeutic opportunities. He has over 25 years of experience in Research & Development of vaccines, biologics and small molecules across an array [...]

31 Aug, 2017

Lloyd Hsu

Lloyd Hsu joined Personalis in May 2015 as VP of Software Engineering. Mr. Hsu owns and drives all aspects of software development, architecture and strategy. Mr. Hsu also leads the IT department and is responsible for ensuring the IT infrastructure aligns with Personalis’ business strategy. Prior to this role, Mr. Hsu spent 4 years as [...]

20 Aug, 2017

Michael Snyder, PhD

Michael Snyder is the Stanford Ascherman Professor and Chair of Genetics and the Director of the Center of Genomics and Personalized Medicine. Dr. Snyder received his Ph.D. training at the California Institute of Technology and carried out postdoctoral training at Stanford University. He is a leader in the field of functional genomics and proteomics. His laboratory study [...]

20 Aug, 2017

Atul Butte, MD, PhD

Atul Butte, MD, PhD is the Priscilla Chan and Mark Zuckerberg Distinguished Professor and inaugural Director of the Institute for Computational Health Sciences ( at the University of California, San Francisco (UCSF). Dr. Butte is also the Chief Data Scientist for the entire University of California Health System, including 17 health professional schools, 6 medical [...]

20 Aug, 2017

Euan Ashley, MD, PhD

Euan Ashley BSc (Hons), MB ChB, MRCP, DPhil, FACC, FAHA Associate Professor of Medicine (Cardiovascular), Director, Stanford Center for Inherited Cardiovascular Disease Co-Director, Training Program in Myocardial BiologyMember, Institute of Medicine Roundtable on Translating Genomic-based Research for Health Director, Stanford Cardiopulmonary Exercise Testing Laboratory Leadership committee, AHA Council on Functional Genomics and Translational Biology Director, [...]

20 Aug, 2017

Vincent Miles

Vincent has more than 30 years of management experience in the biotechnology industry, including over 15 years in Business Development in BioPharmaceuticals. He identifies and invests in new businesses and supports portfolio companies. Vincent is on the boards of Dynex Technologies, Hydra Biosciences, Magellan Diagnostics and Personalis, and has also served on the boards of [...]

20 Aug, 2017

Ken Ludlum

Ken Ludlum is Chairman of the Audit Committee at Personalis and serves as Chief Financial Officer of CareDx, Inc., a molecular diagnostics company. Since April 2019 Mr. Ludlum has served on the board of directors and as Chairman of the Audit Committee of Dermavant Sciences Limited, a United Kingdom company. Ken led the initial public [...]